Clinical Evidence Summary

Most of the weight lost is visceral fat, the dangerous fat that surrounds internal organs, while lean muscle mass is largely preserved. Researchers consider this combination unprecedented for a single compound.

Tirzepatide works on two separate hormone receptors at once, GIP and GLP-1, instead of just one. That dual action is why its effects on appetite and blood sugar build on each other rather than simply adding up.

Researchers also recorded improvements in blood pressure, cholesterol, and triglycerides that were larger than weight loss alone would explain, pointing to a direct metabolic benefit beyond the scale.

Subjects reported real gains in energy and daily function starting around week eight, and those improvements kept building through the entire 72-week study instead of leveling off.

Retatrutide acts on three separate hormone receptors at once, GIP, GLP-1, and glucagon, giving it a third fat-burning pathway that most weight loss compounds do not have.

The added glucagon pathway speeds up how quickly the liver burns stored fat, which is part of why researchers recorded such a sharp drop in liver fat among study participants.

Participants with the most insulin resistance responded the strongest, which matters because that group typically sees the weakest results from older metabolic compounds.

Researchers noted that participants were still losing weight when the study ended, suggesting the results may understate the compound's full effect over a longer period.

Brain imaging showed that semaglutide changes how strongly the brain's reward centers respond to high-calorie food, suggesting it shifts food preference rather than just suppressing hunger.

Semaglutide is the first compound in its category shown to reduce heart attacks, strokes, and cardiovascular deaths in a controlled trial, a benefit that held up independent of how much weight participants lost.

Weight loss held steady for more than two years in an extension study, suggesting the effect reflects a lasting change rather than a temporary suppression of appetite.

Participants also saw major drops in sleep apnea episodes along with real improvements in knee pain and daily physical function.

BPC-157 increases growth hormone receptors directly in tendon tissue and promotes new blood vessel growth at the injury site, the proposed mechanism behind its tendon healing effects.

Inflammation at injury sites dropped sharply within the first week in research models, while range of motion recovered far faster than in untreated control groups.

Gut healing effects showed up within one to two days in research models, with repair documented across ulcers, inflammatory bowel conditions, and other gut lining injuries.

A separate line of research found protective effects on brain cells, including reduced oxidative stress and measurable protection in traumatic brain injury models, a finding outside its original tissue-repair focus.

Unlike many repair peptides that work only where they are applied, TB-500 circulates through the entire body and concentrates at sites of active inflammation, which is why its effects are described as systemic.

At the cellular level, TB-500 regulates the proteins that control cell movement, which researchers believe is the mechanism behind the flexibility and range-of-motion improvements seen in studies.

In cardiac research models, treated subjects formed substantially more new heart muscle cells after injury than untreated controls, pointing to active tissue regeneration rather than simply limiting further damage.

Researchers also documented faster hair follicle regrowth and better scar quality as consistent side findings, observed independently across multiple separate research groups.

Older growth hormone secretagogues like GHRP-2 and GHRP-6 also raise cortisol, which can encourage fat storage and muscle breakdown. Ipamorelin's selectivity lets researchers study growth hormone effects without that trade-off.

Slow-wave sleep increased within two weeks of study initiation, which matters because that sleep stage is when the body naturally releases the most growth hormone and builds the most muscle protein.

IGF-1, the hormone that carries out most of growth hormone's effects on muscle, collagen, and bone, rose well above baseline in study participants.

Researchers also measured a shift toward burning fat for fuel during sleep and fasting periods, with a measurable drop in fat under the skin by 12 weeks.

Because the No DAC form clears the body quickly, it produces a short, sharp pulse of growth hormone release that mirrors the body's natural rhythm rather than a flat, sustained elevation.

Pulsed growth hormone release like this is believed to be more effective for building tissue than constant elevation, and it avoids the receptor downregulation seen with longer-acting versions of the compound.

When paired with a growth hormone secretagogue like Ipamorelin, researchers observed simultaneous gains in lean mass and fat loss without any change to diet, a true shift in body composition rather than simple weight change.

Collagen production rose substantially at 12 weeks, which researchers note is relevant to the strength of tendons, ligaments, joints, and skin.

What makes GHK-Cu unusual is the breadth of its effect. It turns on genes related to tissue repair, antioxidant defense, inflammation control, DNA repair, and stem cell activity all at the same time.

The copper in GHK-Cu is essential for an enzyme called lysyl oxidase, which properly cross-links collagen fibers so repaired tissue ends up structurally strong, not just present.

Multiple independent research groups separately documented increased hair follicle density and thicker hair shafts as a secondary effect, a notably consistent finding across unrelated studies.

In nerve injury models, GHK-Cu promoted regrowth of the protective coating around nerve fibers, leading to faster functional recovery, a finding that extends its relevance beyond skin and connective tissue.

Melanotan 2 produces pigmentation through the same biological pathway as natural UV tanning, which is why the resulting pigment is chemically identical to a regular tan rather than an artificial stain.

Its effect on libido works through a separate receptor in the brain, independent of testosterone, estrogen, or any other sex hormone, which is notable since most libido-related compounds work by altering hormone levels directly.

Appetite reduction shows up within 24 hours in hypothalamic studies, through a pathway that suppresses a specific appetite-driving signal in the brain called neuropeptide Y.

Across the published research, no significant changes to cortisol or sex hormones were detected, and no cardiac, liver, or kidney side effects have been documented.

Tesamorelin is highly selective for visceral fat, the metabolically active fat around internal organs, while leaving fat under the skin and lean muscle largely untouched, a level of selectivity uncommon among fat-loss compounds.

Because it does not reduce lean muscle the way calorie restriction does, researchers consider it a fundamentally different approach to fat loss than diet alone.

A secondary analysis found measurable improvements in executive function among subjects with mild cognitive impairment, a result researchers attribute to rising IGF-1 levels and reduced inflammation from visceral fat.

IGF-1 levels returned to a younger reference range in the majority of subjects over age 50, alongside improvements in bone density markers and cholesterol levels.